M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq BioSpaceAnalysts are cautiously optimistic about an IPO rebound for biopharma.Read full story pharminent May 8, 2026 (Last updated: May 10, 2026) BioSpace Analysts are cautiously optimistic about an IPO rebound for biopharma. Read full story Post navigation Previous: Novo’s CEO champions “record-breaking start” for Wegovy pill in US marketNext: Biogen, Eisai hit with 3-month delay for starting SubQ Alzheimer’s therapy Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
